Physicians' Academy for Cardiovascular Education

Managing the late consequences of CHD: What is the evidence for lipid management

Slides (presentation) - Apr. 15, 2011

Managing the late consequences of CHD
What is the evidence for lipid management

Slides prepared and presented by:
Prof. Phil Barter, MD,
The Heart Research Institute,
Sydney, Australia
At Asian Lipid Master Class
April 2011, Chengdu, China


Click on slides to view presentation


Serum Cholesterol and CHD
Lipoprotein classes and atherosclerosis
ROLE OF LDL IN CAUSING ATHEROSCLEROSIS
Statin Trials: LDL-C Levels vs Events
PROVE-IT:Changes From Baseline LDL-C
PROVE-IT: All-cause Mortality
TNT-Study Design
TNT-Changes in LDL-C By Treatment Group
TNT-Primary Efficacy Outcome Measure
TNT-Stroke
TNT-Primary Endpoint
TNT-Safety
TNT-Major CVE
TNT-Major CVE
TNT-All-cause mortality
TNT-Non-CV mortality
Cardiovascular Mortality in Secondary Prevention Studies
Non-cardiovascular Mortality in Secondary Prevention Studies
Diabetic Subgroup in TNT
Metabolic Syndrome Subgroup in TNT
IDEAL - Protocol
IDEAL: Effect of Treatment On LDL-C
IDEAL: Composite End Points
MIRACL Study Design
MIRACL Results
MIRACL Results
MIRACL Results
MIRACL Conclusion
ARMYDA trial: Study design
Primary end point
ARMYDA trial: Primary end point
ARMYDA trial: Conclusions
All statin clinical outcome trials
Effects of aggressive vs moderate therapy with statins
All statin clinical outcome trials
Aggressive vs moderate statin therapy: effects in diabetes
All statin clinical outcome trials: effects of baseline LDL-C
Aggressive vs moderate therapy: effects of baseline LDL-C
All statin clinical outcome trials: effects of gender
All clinical outcome trials: effects of duration of treatment
All statin clinical outcome trials: effects on Cancer

Download presentation

Share this page with your colleagues and friends: